System medicine is the future of health care, and herbal medicine is playing an essential role
SU Biomedicine obtains European Regional Development Fund (EFRO) grant for “Natural Intelligence in Health” project
In October 2022, Vivaltes B.V. and SU Biomedicine B.V. jointly applied for European Regional Development Fund (EFRO) grant. In January 2023, EFRO project proposal entitled “Natural Intelligence in Health” was approved for 4 years (2023-2026) by the European commission. The aim of this innovative project is to develop and validate the Artificial Intelligence platform to unlock natural resources for the Phyto-pharmaceutical and food industries. In total, seven Dutch project partners (Vivaltes B.V., SU Biomedicine B.V., Universiteit Utrecht, FytagoLife B.V., Single Cell Discoveries B.V., Agrobrains B.V., and Principelle B.V.) work together to integrate Artificial Intelligence with laboratory research and the work encompasses the entire route from small molecules to biological effects. SU Biomedicine B.V. will be involved in investigating the safety of Chinese herbal medicines and create a learning system in which the safety data can be obtained from practices.
Our Story
System medicine is the future of health care, and herbal medicine is playing an essential role
SU BioMedicine is a spin-off company from the Dutch Organization for Applied Scientific Research (TNO). It has developed unique expertise in the field of systems medicine, quality control and international standards of herbal medicine/Chinese medicine, registration and commercialization of herbal products since it was founded in 2004. The core business of SU BioMedicine includes providing scientific evidence with proved safety and efficacy data, providing technical and regulatory supports on international quality standardization of herbal medicine/Chinese medicine, providing consultancy for the EU registration of traditional herbal medicinal products (tHMP), as well as notification, manufacturing g, marketing and sales of food supplements and natural cosmetics in Europe. SU BioMedicine has established numerous collaborations in China and Europe and has a strong network with Chinese universities, innovative industries and research institutes on Chinese medicine. SU BioMedicine has established collaboration with Chinese companies to obtain EU GMP standards for production. SU BioMedicine participated in establishment of Chinese herbal drug monographs according to European pharmacopeia quality standard, Deutscher Arzneimittel-Codex (DAC) and ISO quality standards. SU BioMedicine functions as a bridge between Chinese and European pharmaceutical companies.
Mission
SU BioMedicine works together with Chinese pharmaceutical companies and brings herbal medicinal products to the European market as herbal medicine with scientific proven safety and efficacy to address the worldwide unmet medical need for treatment of various chronic diseases and infectious diseases. e.g. cold and flu. Meanwhile, SU BioMedicine conducts notification for food supplements and creates a new way for Chinese herbal products into EU market.
Perspective
The next generation health care will aim at prevention or treatment of chronic diseases and health promotion. SU BioMedicine is bringing a new generation of herbal medicinal products to the EU market using SU BioMedicine’s vast knowledge on quality control, system medicine and EU legal experiences of herbal medicinal products. SU BioMedicine has numerous collaborations in the world, and establishes networks widely in innovative industries, research institutes on TCM in China and Europe.
Product portfolio
Chinese herbal medicinal products that are used in treatment/ prevention of diseases in the area of pain, woman’s health, cold, etc. Food supplements in the field for supporting the body’s immune function, increasing the antioxidative capacity of the body, supporting a healthy digestion, relieving menopause symptoms, etc.
Technology
Our Expertise
Knowledge on EU regulatory aspects on herbal medicinal products, food supplements, establishment of quality standards for Chinese herbal drugs according to European Pharmacopeia. SU BioMedicine is function as a bridge between China and Europe from scientific and cultural perspectives.
By cooperation with the Leiden University-European Center for Chinese Medicine and Natural Compounds (LUECCM), Oxford University, Cambridge University, Yale University, Chinese academy of Science and China academy of Chinese Medicinal Sciences, etc, SU BioMedicine has established a scientific research platform in discovery and understanding the synergistic and opposing active principles of Chinese herbal medicine and natural compounds by combining scientific technology and novel biological insights. The scientific input can be used as scientific evidence for acceptance of Chinese herbal medicinal products worldwide.
Our in house TCM data base
With its partner Vitaltes BV, SU BioMedicine has developed an in house Traditional Chinese Medicine data base that can serve SU BioMedicine’s clients for safety and efficacy evaluation of the products intend to entering the EU market. In addition, this data base can play a unique role in TCM big data market by providing scientific evidence of TCM products and new TCM product developments.
Products
SUB creates value by its own and shared products, and provides services for a portfolio of approved Chinese herbal products and developing markets.
Traditional herbal medicinal product: DXXK
SU BioMedicine has realized as the first company in the world the registration of a Chinese medicine product produced in China according to tHMP (traditional Herbal medicinal product) rules (directive 2004/24/EC) in Europe that . A press conference on this was given on April 18, 2012 and organized by the Chinese government minister of Health Chen Zhu, the vice president of the National People’s congress San Guo Wei and the Chinese Academy of Sciences in the prestigious People’s Hall in Beijing. Present were 400 people from the press including CCTV.
SU BioMedicine supported Tasly Group to successfully conduct the EU registration of Danshen Capsule (2016) and Xiao Yao tablet (2021) according to tHMP (traditional Herbal medicinal product) in the Netherlands.
In 2018, SU BioMedicine assisted HuaSun Pharmaceutical Group to facilitate the Refined Notoginseng Root Dry Extract entering Deutscher Arzneimittel-Codex (DAC), and further promoted to enter German pharmacopeia (DAB) monograph.
Food supplements: Defender-YPF
SU BioMedicine jointly with Gaocao doctor conducted the EU notification of a food supplement from a classic herbal formula (Yu ping feng) for supporting the body’s immune function to improve the body’s natural defense function and successfully obtained KAG-nr. and PL nr. It creates a new legal path for traditional Chinese herbal products as food supplements to enter the EU market.
More information about scientific evidence on safety, efficacy and quality control of Defender-YPF.
News
2023
Dr. Mei Wang attended a Webinar called “The Therapeutic Potential of Phytomedicines” organized by The Dutch association of phytotherapy (NVF)
2022
Dr. Mei Wang has obtained an outstanding prize “International award for contribution to Chinese medicine -achievement award 2022”
December 2022
Dr. Mei Wang on behalf of SU BioMedicine together with State Key Laboratory of Component-Based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China jointly published the review article “Herbal medicine in the treatment of COVID-19 based on the gut-lung axis” in Acupuncture and Herbal Medicine. DOI: 10.1097/HM9.0000000000000038
2022
SU BioMedicine team together with institutes from Germany, the Netherlands and China jointly published the review article “Market access for Chinese herbal medicinal products in Europe—A ten-year review of relevant products, policies, and challenges” in Phytomedicine. DOI: 10.1016/j.phymed.2022.154237
2022
SU BioMedicine team together with Institute of Chinese Medical Sciences, and State Key Laboratory of Quality Research in Chinese Medicine, University of Macau jointly published the review article “Key quality factors for Chinese herbal medicines entering the EU market” in Chinese Medicine. DOI: 10.1186/s13020-022-00583-x
2021
SU BioMedicine conducted the EU notification of a food supplement for Defender-YPF and successfully obtained KAG-nr. and PL nr.
2021
SU BioMedicine supported Tasly Group to successfully complete the EU registration of the Xiao Yao tablet product according to tHMP (traditional Herbal medicinal product) in the Netherlands.
2020
SU BioMedicine assisted HuaSun Pharmaceutical Group to promote the Refined Notoginseng Root Dry Extract entering German pharmacopeia (DAB) monograph.
2019
International Forum on Traditional Chinese Medicine and Botanical Medicine in Shenzhen, China: For more information, please see the promotional film.
2018
SU BioMedicine assisted HuaSun Pharmaceutical Group to promote the Refined Notoginseng Root Dry Extract entering Deutscher Arzneimittel-Codex (DAC) monograph.
2017
XIX Pharmaceutical Congress of São Paulo, Brazil
2017
Traditional Medicine International Cooperation Forum (2017 TMIF), Macao, China
2012
SU BioMedicine’s project with Diao was chosen as one of the 10 most scientific innovative achievements by the Chinese Academy of Sciences, Chinese Academy of Engineering, the Ministry of Science and Technology and the Nature Science foundation.
Qihuang Prize
Qihuang prize awarded to Mei Wang
Dr. Mei Wang, CEO of SU Biomedicine, has been awarded the ‘Qihuang prize’ by the Chinese Medicine Society in recognition of her significant contributions to traditional Chinese medicine (TCM) in the world. Chinese minister of health Mr. Guo Qiang Wang presented this award to Dr. Mei Wang on 25th Nov 2018 in Beijing, China. The aim of the Qihuang prize is to recognize her significant contributions and encourage her to contribute even more to TCM in the world by stimulating her initiatives and creativity with the honor.
Combining the best of both worlds
Dr. Mei Wang has studied and made efforts to integrate TCM with modern science and technology from different scientific perspectives and cultural backgrounds. She has been working for more than ten years as an expert in the TCM working group for the European pharmacopoeia, a single reference-work for official European quality standards. As a rapporteur, she contributed to establish more than twenty quality monographs of Chinese herbal drugs for the European pharmacopoeia. ‘It is a great honor for me to receive the Qihuang prize, and I am happy to be recognized for my research and activities for TCM’ – said Mei Wang.
The future…
Dr. Mei Wang will continue to dedicate to the study and promotion of TCM in the world. ‘Scientific proof and insight into the underlying mechanisms is key for acceptance of TCM in western society.
It is my ambition to provide all the people from the world access to the benefits of the TCM treasure house which contains rich and valuable knowledge’ – says Wang